Kraig Biocraft Laboratories (Kraig Biocraft Laboratories) Operating Income : $-2.62 Mil (TTM As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Kraig Biocraft Laboratories Operating Income?

Kraig Biocraft Laboratories's Operating Income for the three months ended in Dec. 2023 was $-1.19 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.62 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Kraig Biocraft Laboratories's Operating Income for the three months ended in Dec. 2023 was $-1.19 Mil. Kraig Biocraft Laboratories's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Kraig Biocraft Laboratories's Operating Margin % for the quarter that ended in Dec. 2023 was %.

Kraig Biocraft Laboratories's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kraig Biocraft Laboratories's annualized ROC % for the quarter that ended in Dec. 2023 was -202.21%. Kraig Biocraft Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -2,788.37%.

Kraig Biocraft Laboratories Operating Income Historical Data

The historical data trend for Kraig Biocraft Laboratories's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kraig Biocraft Laboratories Operating Income Chart

Kraig Biocraft Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Income

Get a 7-Day Free Trial

-2.62

-4.53

-2.76

-2.12

-2.62

Kraig Biocraft Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Income	Get a 7-Day Free Trial															-0.51	-0.49	-0.48	-0.46	-1.19

Kraig Biocraft Laboratories Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.62 Mil.

Kraig Biocraft Laboratories (OTCPK:KBLB) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kraig Biocraft Laboratories's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-4.752 * ( 1 - 0% )	/	( (2.347	+	2.353)	/ 2 )
=	-4.752	/	2.35
=	-202.21 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.627	-	6.851	-	( 2.895	-	max(0, 8.571	-	3	+	2.895	))
=	2.347

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.233	-	7.192	-	( 2.552	-	max(0, 8.886	-	2.574	+	2.552	))
=	2.353

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Kraig Biocraft Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-4.796	/	( ( (0.182 + max(-6.746, 0))	+	(0.162 + max(-7.17, 0)) )	/	2 )
=	-4.796	/	( ( 0.182	+	0.162 )	/	2 )
=	-4.796	/	0.172
=	-2,788.37 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.007	+	0.098)	-	(6.851	+	0	+	0)
=	-6.746

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.007	+	0.015)	-	(7.192	+	0	+	0)
=	-7.17

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Kraig Biocraft Laboratories's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1.188	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

Kraig Biocraft Laboratories Operating Income Related Terms

Thank you for viewing the detailed overview of Kraig Biocraft Laboratories's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Kraig Biocraft Laboratories (Kraig Biocraft Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Kraig Biocraft Laboratories Inc (OTCPK:KBLB) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

2723 South State Street, Suite 150, Ann Arbor, MI, USA, 48104

Website

https://www.kraiglabs.com

Kraig Biocraft Laboratories Inc is engaged in the development of high-strength fibers using recombinant DNA technology mainly for commercial applications. It uses genetic engineering technologies to develop fibers with greater strength, resiliency, and flexibility for use in its target markets, namely the textile, specialty fiber, and technical textile industries. Its products include Monster Silk, which incorporates the natural elasticity of spider silk to make a silk fiber that is more flexible than conventional silk fibers and textiles; and Dragon Silk, which combines the elasticity of Monster Silk with additional high strength elements of native spider silk; Spydasilk; and Spydra. It generates the majority of its revenues from its business across the United States.

Executives

Jonathan Richard Rice	officer: COO	2723 S STATE STREET, SUITE 150, ANN ARBOR MI 48104
Kimberly Kraig Thompson	director, 10 percent owner, officer: CEO, CFO	2723 S STATE STREET, SUITE 150, ANN ARBOR MI 48401